257 related articles for article (PubMed ID: 21060169)
21. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
22. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
23. [Controversies about the use of calcineurin inhibitors in pediatric patients].
Dello Strologo L
G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
[TBL] [Abstract][Full Text] [Related]
24. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S
J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168
[TBL] [Abstract][Full Text] [Related]
25. Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation.
Barraclough KA; Staatz CE; Isbel NM; McTaggart SJ
Nephrology (Carlton); 2010 Aug; 15(5):522-32. PubMed ID: 20649871
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
Schiff J; Cole E; Cantarovich M
Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
[TBL] [Abstract][Full Text] [Related]
28. [Low-toxicity immunosuppressive therapy in renal transplant].
Scolari F; La Manna G; Comai G; Cappuccilli ML; Todeschini P; Ciavatti A; Persici E; Feliciangeli G; Stefoni S
G Ital Nefrol; 2007; 24 Suppl 38():44-8. PubMed ID: 17922447
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive agents in organ transplantation: past, present, and future.
Hong JC; Kahan BD
Semin Nephrol; 2000 Mar; 20(2):108-25. PubMed ID: 10746855
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
31. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
32. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Transplant Proc; 2006 Dec; 38(10):3239-40. PubMed ID: 17175234
[TBL] [Abstract][Full Text] [Related]
33. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.
Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; van Gelder T; Sallustio BC
Ther Drug Monit; 2011 Dec; 33(6):688-93. PubMed ID: 22105584
[TBL] [Abstract][Full Text] [Related]
34. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests.
Israeli M; Ben-Gal T; Yaari V; Valdman A; Matz I; Medalion B; Battler A; Sredni B; Kristt D; Klein T
Transplantation; 2010 Apr; 89(8):968-76. PubMed ID: 20075792
[TBL] [Abstract][Full Text] [Related]
35. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
Blanchet B
Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
[TBL] [Abstract][Full Text] [Related]
36. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
37. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
38. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
39. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
40. Conclusions from the symposium.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S47-8. PubMed ID: 21095453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
